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INCREASED plasma- and tissue levels of endothelin-1 (ET-
1) during inflammatory diseases, have suggested a role of
ET-1 in the pathophysiology of inflammatory reactions.
The authors have studied the effect of ET-1 on cytokine
release from monocytes and monocyte-derived macro-
phages. ET-1 increased secretion of TNF-, IL-1/I and
IL-6 in a dose- and time-dependent manner. Optimal ET-1
concentration ranged from 0.01 to 1 nM. The maximal
response was a 200 to 400% increase in cytokine release.
A time-course study revealed that the pattern of cytokines
induced by ET-1 was different in monocytes and macro-
phages, although an early increase in TNF-ffwas observed
in both monocyte and macrophage supernatants. In con-
clusion, ET-1 stimulates monocytes and macrophages to
release cytokines thereby demonstrating a potential role
for ET-1 in regulation of inflammatory responses.
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Introduction
Endothelin-1 (ET-1) was originally described as
a potent vasoactive peptide released from en-
dothelial cells. 1’2 The observation that macrophages
and mast cells both release and have receptors for
ET-1, has suggested that ET-1 possibly plays a role
as a modulator of monocyte/macrophage func-
tion. 3,4
Increased plasma- and tissue levels of ET-1 are
reported in patients with inflammatory diseases
such as rheumatoid arthritis, Mb.Crohn and septic
shock.
5- Elevated plasma levels of ET-1 are even
associated with the severity of illness in patients
with septicaemia. Furthermore, in a recent study
the authors have shown that ET-1 increases
microvascular permeability in isolated rat lungs
provided leukocytes are present in the perfusate.
Against this background we hypothesized that
ET-1 might play a role in the pathophysiology of
inflammatory reactions. Therefore an investigation
into whether ET-1 stimulation of monocytes and
macrophages induced release of inflammatory
mediators such as TNF-, IL-I and IL-6, was
required. These cytokines play an important role in
the development of inflammatory diseases.9’
Synergistic actions of these cytokines are further
suggested to be of crucial importance for the
outcome of septic shock.
9-1
In the present study human monocytes and
monocyte-derived macrophages were stimulated in
vitro with ET-1 for specific time intervals, and the
secretion of TNF-oq IL-I and IL-6 in the
supernatants was measured by bioassay.
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Materials and Methods
Reagents: Endqthelin-1 (human) and endothelin
antiserum were obtained from Nova Biochem
(Liiufelingen, Switzerland). Human rTNF<z with
specific activity 2.0 x 107 U/mg, monoclonal anti-
human TNF-0 antibodies, human rlL-6 with
specific activity 2.0 x 108 U/mg and monoclonal
anti human IL-6 antibodies were obtained from
Boehringer-Mannheim (Mannheim, Germany).
Human rlL-1/g with specifiC activity 2.0 x
108 U/mg, and goat polyclonal anti-human IL-lfl
antibodies were purchased from British Bio-
technology (Oxon, UK).
Isolation and cultivation of monocytes and monocyte-derived
macrophages: Highly purified monocytes were ob-
tained using the method described previously.
2
Briefly, unseparated mononuclear cells (PBMC)
were isolated from buffy coat (The Blood Bank,
University Hospital of Tromso, Tromso, Norway)
by density centrifugation with Lymphoprep (Lym-
phoprep, Nycomed Pharma AS, Oslo, Norway).
The cells were washed three times with HBSS
(Gibco, Glasgow, UK) and resuspended in medium
consisting of RPMI-1640 with 100 IU/ml penicillin,
100/.zg/ml streptomycin, and supplemented with
25% human serum. Peripheral blood mononuclear
cells (PBMC) were then seeded in 24-well culture
plates (Falcon, Becton Dickinson Labware, NJ,
USA) in concentration of 2 x 106 cells/well.
After incubation at 37C for 90 min the cell
cultures were washed three times with pre-warmed
RPMI-1640 to remove non-adherent cells. Mono-
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cyte cultures were either stimulated with ET-1
immediately, or further cultivated for 10 days to
obtain monocyte-derived macrophages. The cells
were assessed morphologically with Wright stain,
showing > 90% monocytes, and their viability was
> 90% as determined by Trypan blue exclusion.
Stimulation ofmonocytes and monocyte-derived macrophages with
ET- The monocyte and macrophage cultures were
incubated with various concentrations of ET-1
ranging from 0.005 nM to 100 nM or medium only
(controls) for 1, 4, 8 and 24 h. To exclude endotoxin
contamination, cell cultures were incubated with
ET-1 denaturated by boiling for 30 min. Further-
more, in some experiments ET-1 was pre-incubated
with ET-1 antiserum prior to addition to the cell
cultures. For positive controls, cultures were
incubated with LPS 0.1 g/ml for 24h. The
supernatants were harvested at the time points
indicated and stored at -20C before being
analysed for TNF<z, IL-lfl and IL-6. Supernatants
and ET-1 were tested for endotoxin using an
Endospecy kit (Seikagaku Kogyo Co. Ltd, Tokyo,
Japan). No significant amounts of endotoxin were
detected.
Detection of TNF-" TNF-0 activity was determined
by its cytotoxic effect on the fibrosarcoma cell line
WEHI 164 clone 13, as described previously.
13
Briefly, target cells were seeded in 96-well
microplates (Falcon, Becton Dickinson Labware,
Nj, USA) with different dilutions of culture
supernatants from ET-1 stimulated monocytes and
macrophages and incubated for 24 h at 37C.
Serial dilutions of human rTNF- (Boehringer-
Mannheim) were included as a standard. The
TNF-0 specificity of the assay was verified using a
monoclonal antibody against rTNF-0 (Boehringer-
Mannheim, Germany), which completely neutral-
ized the detected activity (data not shown). Results
are presented as pg/ml +_ S.D. of triplicate
determinations.
Detection ofIL-lfl: IL-1/ activity was determined by
a two-stage bioassay. The first stage involves the
mouse thymocyte IL-4 NOB-1 cell line, which
produces high amounts of IL-2 in response to
human IL-lfl.
14 Serial dilutions of human rlL-lfl
were included as standard. NOB-1 cells were seeded
in 96-well microplates with different dilutions of
culture supernatants and incubated for 24 h at 37C.
Then, 100/1 aliquots of the supernatants were
transferred to a replicate 96-well microplate for the
next stage. This stage of the assay involved the IL-2
dependent mouse T-cell line HT-2.s Aliquots
(100/1) of HT-2 cell suspension (1.5 x 108 cells/
well) were added to each well of the replicate
microplate and incubated for a further 24 h. The
IL-lfl activity was neutralized by a polyclonal
antibody against rIL-lfl (British Bio-technology)
(data not shown). Results are presented as
pg/ml S.D. of triplicate measurements.
Detection ofIL-6:IL-6 activity was determined using
the IL-6 dependent mouse hybridoma cell line
B.13.29 clone 9.16 Briefly, serial dilutions of culture
supernatants and rlL-6 as a standard, were
incubated in 96-well microplates with cells (5 103
cells/well), in a total volume of 200/1, at 37C for
72h. IL-6 bioactivity was neutralized by a
monoclonal antibody against rlL-6 (Boehringer-
Mannheim, Germany) (data not shown). Results are
presented as pg/ml -+- S.D. of triplicate determina-
tions.
MTT assay: Viability of the cells in the assays for
TNF-0, IL-1/ and IL-6 were tested by incubation
with MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl-tetrazolium bromide] (Sigma, USA) as de-
scribed previously.
5 Microplates were read at
570 nm (ODsT0) on a NovaPathTM Mini Reader (Bio
Rad, Richmond, CA, USA).
Results
ET-1 stimulates monocytes and macrophages to release
TNF-, IL-lfl and IL-6: There was a donor to
donor variability in the levels of cytokines
produced in unstimulated control cultures, as also
reported by others. 17 However, the response
pattern seen after ET-1 stimulation was generally
the same in cultures of mononuclear phagocytes
obtained from different donors. Figure 1 depicts the
dose-response of ET-l-induced secretion ofTNF-
(a), IL-lfl (B) and IL-6 (C) from monocytes and
macrophages. The concentrations of TNF-0, IL-lfl
and IL-6 measured in the supernatants showed an
inverse U-shaped dose-response curve. The max-
imal cytokine production was observed in a
concentration range of 0.01-1 nM ET-1. In this
range the optimal ET-1 concentration appeared to
be donor dependent. Furthermore, as shown in Fig.
1, monocytes secreted generally more TNF-0 and
IL-lfl than macrophages in response to ET-I
stimulation. Denaturation by boiling or pre-
incubation with ET-1 anti-serum, neutralized
the effect of ET-1 on cytokine release from
monocytes and macrophages (data not shown).
For comparison, Table 1 shows the response to
LPS 0.1/g/ml. After 24h, LPS stimulation
caused a strong five- to ten-fold increase in release
of TNF-0, IL-lfl and IL-6 from monocytes and
macrophages.
Kinetics of ET-1 induced TNF-o release from monocytes and
macrophages: As shown in Fig. 2A, the time-course
study revealed that ET-1 stimulation had increased
monocyte TNF- production after 1 h incubation.
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FIG. 1. Endothelin-1 (ET-1)-induced release ofTNF- (A), IL-lfl (B) and
IL-6 (C) from human monocytes and monocyte-derived macrophages.
Monocyte and macrophage cultures were incubated with different
concentrations of ET-1 or medium only (C" controls). Data represent
the mean ___
S.D. of triplicate measurements of one of three representative
experiments performed in duplicate.
macrophages.
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FIG. 2. The time-course study of endothelin-1 (ET-1)-induced release of
TNF- (A), IL-6 (B), and IL-lfl (C) from monocytes and macrophages in
response to 0.1 nM ET-1. This ET-1 concentration was in the optimal
range for maximal cytokine release as shown in Fig. 1. The monocyte and
macrophage cultures were stimulated with ET-1 for 1,4, 8 and 24 h. The
results are expressed in % of controls, and given as the mean value 4- S.D.
of three to four experiments performed in duplicates. I, monocytes; [],
macrophages.Endothelin stimulates cytokine release
Table 1. LPS-induced secretion of TNF-z, IL-lfl and IL-6 by
monocytes and monocyte-derived macrophages
Cytokine Cells Controls LPS, 0.1 #g/ml
(pg/ml) for 24 h (pg/ml)
TNF- Monocytes 290 _+ 13 2008 _+ 81
Macrophages 109 _+ 10 585 _+ 70
IL- fl Monocytes 109 _+ 15 3876 _+ 79
Macrophages 225 _+ 50 814 _+ 13
IL-6 Monocytes 202 +_ 40 1226 +_ 78
Macrophages 163 _+ 30 1246 _+ 34
The monocyte and macrophage cultures were incubated with
LPS 0.1 #g/ml or medium alone (controls) for 24 h. The culture
supernatants were analysed for TNF-z. L-lfl and L-6 as
described under Materials and Methods.
TNF-0 production continued to increase by 4 h and
reached a maximum, with three-fold increase, by
8h.
In the macrophage culture supernatants, ET-1
had increased TNF-0 production three-fold by 1 h;
whereas by 4h and 8 h the TNF- level had
returned to baseline. By 24 h the TNF- level had
increased by 250%.
Kinetics of ET-l-induced IL-6 release from monocytes and
macrophages: As shown in Fig. 2B, ET-1 increased
monocyte IL-6 production slightly after 4h
stimulation, and levels were still elevated at 24 h.
In the macrophage cultures ET-1 had induced
IL-6 production by 1 h, reaching a two-fold peak
concentration in the supernatants within 4 h, and
declining, but still increased as compared with
controls, by 24 h.
Kinetics of ET-l-induced IL-1 release from monocytes and
macrophages: As shown in Fig. 2C, ET-1 increased
monocyte IL-lfl production, as measured in the
supernatants, after 8 h, reaching more than a
two-fold increase by 24 h. In macrophage super-
natants increased IL-lfl levels were detected by 4 h,
reaching a maximal two-fold increase after 24 h. No
release of IL-1/ was detected in monocyte or
macrophage supernatants after 1 h incubation time.
Discussion
The present results show that ET-I stimulates
human monocytes and macrophages to release
TNF-0, IL-lfl and IL-6 in a dose- and time-
dependent manner. So far, the potential of ET-1 to
aect immune and inflammatory cells is largely
unexplored. The only previously encountered study
was done by Millull et al., who demonstrated that
ET-1 stimulation of alveolar macrophages increased
arachidonic acid (AA) release by a maximal 300%.
18
In the present study, the same concentration range
of ET-1, 0.1 to 1 nM, induced an optimal response
with a 200 to 400% increase in cytokine release.
The monocyte cultures secreted generally more
TNF-z and IL-lfl than did the macrophage
cultures, in response to ET-1. The same pattern was
observed after LPS stimulation in the present study.
These findings are in accordance with previous
studies, concluding that the capacity of mono-
nuclear phagocytes to secrete TNF-0 and IL-1/ may
vary with their state of dit:ferentiation.19’2
Stimulation with 0.1 #g/ml LPS caused a five- to
ten-fold increase in cytokine release from mono-
cytes and macrophages. The generally lower release
of cytokines in response to ET-1, indicates that LPS
and ET-1 activate dierent mechanisms for
cytokine release in mononuclear phagocytes.
Denaturating ET-1 by boiling did not increase
cytokine production, which excludes the possibility
that the observed eect of ET-1 was caused by
contamination with endotoxin.
The time-course study revealed a sequential
release of TNF-, IL-lfl and IL-6 from both
monocytes and macrophages. TNF-0 was released
prior to IL-lfl and IL-6. A similar pattern was
reported previously after LPS stimulation of
mononuclear phagocytes in vitro, in septicaemia in
experimental animals and in patients with meningo-
coccal septic shock.9’11’20 Previous reports have also
documented that TNF-0, IL-lfl and IL-6 might
interact on the production and release of each
other. 1’11’17’21 IL-6 has been reported to suppress
TNF-0 production in mononuclear phagocytes. 17’22
This might explain the reduction of TNF-0
observed in the macrophage supernatants in
parallel with the peak concentration of IL-6. In the
monocyte cultures, ET-1 caused only a slight
increase in IL-6 secretion, and no parallel reduction
of TNF-0 was observed. This also demonstrates
that ET-1 induces a differential modulation of
TNF-0 and IL-6 secretion from monocytes and
macrophages.
In experimental animals TNF- is shown to cause
a leukocyte dependent lung injury, and to increase
microvascular permeability in the pulmonary
circulation.
23 Thus the ET-1 induced TNF-0
secretion from monocytes and macrophages as
shown in the present study, might explain the
earlier observation of ET-1 induced leukocyte
dependent lung injury in isolated rat lungs.
8
In patients with septic shock, plasma levels of
ET-1 have been reported to be 20 pg/ml. This
coincides with the lower range of the ET-1
concentrations causing cytokine release from
monocytes and macrophages in the present study.
However, many workers favour the belief that
ET-1 primarily functions in an autocrine manner,
and that circulating levels of ET-1 only reflect an
overflow to the circulation, indicating that local
concentrations of ET-1 are substantially higher.
2
The present observations extend the under-
standing of ET-1 as a vasoactive peptide, and
Mediators of Inflammation Vol 2.1993 421E. Helset et al.
Vascular
smooth muscle
Activated tissue
macrophage
TNF-=
IL-6
IL-1
Monocyte
TNF.= "
IL.6
IL.1 E LAM-1
Vascular
endothelium
CAM
RBC ET-1
Thrombin
Shear stress
TNF.=
Ischaemia
ET-1 )
Activated tissue
macrophage
FIG. 3. Endothelin-1 (ET-1) is reported to be released from endothelial cells in response to thrombin, endotoxin, TNF- and injury caused by ischaemia
and shear stress.2’24-27 In the present study it is documented that ET-1 stimulates monocytes and macrophages to release TNF-0, IL-1/t and IL-6. These
results suggest a new possibility for interactions between mononuclear phagocytes and endothelial cells.
demonstrate that ET-1 is capable of activating
mononuclear phagocytes, thereby causing release of
TNF-0, IL-lfl and IL-6. The present results also
suggest a new possibility for the interactions
between endothelial cells and macrophages, as
illustrated in Fig. 3.
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